HIGHLIGHTS
- who: Lita A. Freeman from the Institut have published the research work: Plasma lipoprotein-X quantification on filipin-stained gels: monitoring recombinant LCAT treatment ex vivo, in the Journal: (JOURNAL)
- what: This trial demonstrated that enzyme replacement therapy with rhLCAT is a potential strategy for increasing HDL-C in FLD; however, the effect of rhLCAT on LP-X was not examined. After completion of this study, a more potent formulation of rhLCAT, MEDI6012, with a longer half-life was developed and is now being tested in patients with cardiovascular disease in a phase II clinical . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.